Study analysis · JAMA pediatrics · 2022
Kids felt less pain after taking a sugar-water pill—knowing full well it had no medicine.
Even when kids know they're taking a fake pill, it still helps reduce their stomach pain and medicine use.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study showed that when kids were told they were taking a sugar pill with no medicine, their tummy pain got a little better. But since they and their doctors knew they were taking the sugar pill, we can't be 100% sure it was the pill itself that helped—or if it was just because they felt cared for or expected to feel better.
What’s the bottom line?
Kids with tummy pain were given a harmless liquid they were told was a placebo — and told honestly that placebos can sometimes help. They took it twice a day for 3 weeks, then had 3 weeks with no treatment.
How strong is this study?
This study did a good job by randomly assigning kids to different treatment orders and having someone else measure their pain without knowing which treatment they got. But because everyone knew what treatment they were getting, it’s like a race where some runners know the finish line—so we have to be careful trusting that the sugar pill alone made all the difference.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
60 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample size (n=30)+2.8/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, the lack of blinding introduces potential performance and detection bias, which may inflate the observed effect. However, the crossover design, intention-to-treat analysis, and blinded outcome assessment strengthen causal inference despite unblinded participants and clinicians.
Minor COI
Minor conflicts that may slightly influence the study
Several authors disclosed financial relationships with pharmaceutical companies, but these were unrelated to the study and did not involve direct funding or control over the research. The study was primarily funded by government and nonprofit sources.
Funders
Conflict Details
Innovative Health Solutions: Received personal fees outside the submitted work
Sucampo: Received personal fees outside the submitted work
Takeda: Received personal fees outside the submitted work
QOL Medical: Served as advisor outside the submitted work
Innovative Health Solutions: Served as advisor outside the submitted work
+8 more conflicts
Independent Analysis Safeguards
- Funding sources had no role in design, conduct, data analysis, interpretation, manuscript preparation, review, approval, or publication decisions
- Dr. Nurko had full access to all data and took responsibility for data integrity and accuracy
Although multiple authors have ties to pharmaceutical companies, these relationships are disclosed as external and unrelated to the study. The primary funders are government and nonprofit entities, and there is no evidence of industry influence on study design or outcomes. The study's methodology and transparency in reporting reduce bias risk.
Key takeaways
- 01
Pain went down by 5.2 points on a 100-point scale, and kids used 1.8 fewer pain pills.
- 02
But only 47% said they felt better overall — not a big jump.
- 03
Their parents' hopes didn't predict who got better.
- 04
A 5-point drop in pain and nearly 2 fewer pills per week is meaningful for kids with chronic stomach pain — it means less discomfort and less need for medicine.
Surprising findings
- Children who didn’t believe the placebo would work still experienced significant pain reduction.Common belief is that placebo effects require conscious expectation or deception—this study proves the opposite: belief isn’t necessary for benefit.
- 53.3% of children took fewer rescue pills during the placebo period—even though they knew it was fake.Rescue medication use is an objective, measurable behavior—this isn’t just about feeling better, it’s about actual changes in health-seeking behavior.
Practical takeaways
If your child has chronic stomach pain, ask their doctor about trying a transparent open-label placebo as a low-risk, drug-free option.
This was tested only in kids with functional abdominal pain or IBS—results may not apply to other conditions or younger children.
medium confidenceTrack your child’s daily pain and medication use for 3 weeks before and after trying a placebo—use a simple 0–100 scale to measure change.
Don’t replace proven treatments without medical advice—this is a potential adjunct, not a cure.
medium confidenceWhy this study matters
Placebos Work—Even When You Know They're Fake
In a study of 30 children with chronic stomach pain, taking 1.5 mL of inert sugar syrup twice daily for 3 weeks reduced daily pain scores by 5.2 points on a 100-mm scale and cut rescue medication use by 1.8 pills compared to no treatment.
This shatters the myth that placebos only work if you're tricked—showing that honesty and biology can still produce real relief, which could change how doctors treat chronic pain without drugs.
Parents' Hope Didn't Predict Results
Despite parents believing the placebo might help, their expectations had no link to whether their child improved. Even kids who didn’t believe it would work still saw pain drop by an average of 5.2 points.
It means the placebo effect isn’t just about belief—it’s something deeper, maybe subconscious or physiological, which makes it even more mysterious and powerful.
Pain Dropped, But Kids Didn’t Feel 'Better'
While daily pain and medication use improved, only 47% of kids reported feeling 'globally better'—a statistically insignificant change compared to the control period.
This reveals a disconnect between objective symptom relief and subjective well-being—suggesting pain reduction doesn’t always translate to feeling 'cured,' which is crucial for parents and clinicians.
No Side Effects—Just Sugar Water
The inert placebo (85% sucrose suspension) caused zero adverse effects, even in children with sensitive digestive systems, making it one of the safest interventions ever tested for pediatric abdominal pain.
Imagine a treatment that reduces pain and pills without risks—this could be a game-changer for families tired of side effects from medications like hyoscyamine.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Kids with tummy pain were given a harmless liquid they were told was a placebo — and told honestly that placebos can sometimes help. They took it twice a day for 3 weeks, then had 3 weeks with no treatment.
Research results
Pain went down by 5.2 points on a 100-point scale, and kids used 1.8 fewer pain pills. But only 47% said they felt better overall — not a big jump. Their parents' hopes didn't predict who got better.
What this means - more context
A 5-point drop in pain and nearly 2 fewer pills per week is meaningful for kids with chronic stomach pain — it means less discomfort and less need for medicine.
To evaluate whether open-label placebo (OLP), administered transparently without deception, can reduce pain and medication use in children and adolescents with functional abdominal pain or irritable bowel syndrome.
In a crossover randomized trial of 30 children aged 8–18, OLP (1.5 mL inert suspension twice daily for 3 weeks) significantly reduced daily pain scores by 5.2 points on a 100-mm scale and decreased rescue medication use by 1.8 pills compared to a no-treatment control period. Global self-reported improvement was not significantly different, and no adverse effects were observed. Expectations did not predict response. This study has published corrections; readers should consult errata for updated information.
Methods Used
Multicenter, crossover, randomized clinical trial with intention-to-treat analysis; 30 children with Rome III-defined functional abdominal pain or IBS received 3 weeks of open-label placebo (1.5 mL inert suspension twice daily) and 3 weeks of no treatment in counterbalanced order; daily pain (0–100 mm visual analog scale) and rescue medication use were primary outcomes; all assessments were blinded.
Main Finding
Open-label placebo significantly reduced daily pain scores by 5.2 points (95% CI, 0.2–10.1; P = .03) and decreased rescue medication use by 1.8 pills (95% CI, 0.5–3.1; P < .001) compared to no treatment, with no adverse effects and no association between expectations and response.
Confidence Level
Moderate; randomized crossover design with blinded outcome assessment and intention-to-treat analysis increases reliability, but lack of blinding of participants and clinicians introduces potential bias; small sample size (n=30) limits generalizability.
Study Flags
Red Flags
- •No blinding of participants or clinicians
- •Small sample size (n=30)
- •Short follow-up (3 weeks per period)
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Children who didn’t believe the placebo would work still experienced significant pain reduction.
Common belief is that placebo effects require conscious expectation or deception—this study proves the opposite: belief isn’t necessary for benefit.
Practical Takeaways
If your child has chronic stomach pain, ask their doctor about trying a transparent open-label placebo as a low-risk, drug-free option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study showed that when kids were told they were taking a sugar pill with no medicine, their tummy pain got a little better. But since they and their doctors knew they were taking the sugar pill, we can't be 100% sure it was the pill itself that helped—or if it was just because they felt cared for or expected to feel better.
Minor conflicts detected — such as academic funding or advisory roles. These are common and have a small score impact.
Strengths
- Randomized controlled trial design with crossover structure
- Intention-to-treat analysis
- Blinded outcome assessment by research assistants
Weaknesses
- No blinding of participants or clinicians (open-label design)
- Small sample size limits precision and subgroup analyses
- Potential for performance bias due to unblinded clinicians
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Kids with tummy pain were given a harmless liquid they were told was a placebo — and told honestly that placebos can sometimes help. They took it twice a day for 3 weeks, then had 3 weeks with no treatment.
Research results
Pain went down by 5.2 points on a 100-point scale, and kids used 1.8 fewer pain pills. But only 47% said they felt better overall — not a big jump. Their parents' hopes didn't predict who got better.
What this means - more context
A 5-point drop in pain and nearly 2 fewer pills per week is meaningful for kids with chronic stomach pain — it means less discomfort and less need for medicine.
To evaluate whether open-label placebo (OLP), administered transparently without deception, can reduce pain and medication use in children and adolescents with functional abdominal pain or irritable bowel syndrome.
In a crossover randomized trial of 30 children aged 8–18, OLP (1.5 mL inert suspension twice daily for 3 weeks) significantly reduced daily pain scores by 5.2 points on a 100-mm scale and decreased rescue medication use by 1.8 pills compared to a no-treatment control period. Global self-reported improvement was not significantly different, and no adverse effects were observed. Expectations did not predict response. This study has published corrections; readers should consult errata for updated information.
Methods Used
Multicenter, crossover, randomized clinical trial with intention-to-treat analysis; 30 children with Rome III-defined functional abdominal pain or IBS received 3 weeks of open-label placebo (1.5 mL inert suspension twice daily) and 3 weeks of no treatment in counterbalanced order; daily pain (0–100 mm visual analog scale) and rescue medication use were primary outcomes; all assessments were blinded.
Main Finding
Open-label placebo significantly reduced daily pain scores by 5.2 points (95% CI, 0.2–10.1; P = .03) and decreased rescue medication use by 1.8 pills (95% CI, 0.5–3.1; P < .001) compared to no treatment, with no adverse effects and no association between expectations and response.
Confidence Level
Moderate; randomized crossover design with blinded outcome assessment and intention-to-treat analysis increases reliability, but lack of blinding of participants and clinicians introduces potential bias; small sample size (n=30) limits generalizability.
Study Flags
Red Flags
- •No blinding of participants or clinicians
- •Small sample size (n=30)
- •Short follow-up (3 weeks per period)
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Children who didn’t believe the placebo would work still experienced significant pain reduction.
Common belief is that placebo effects require conscious expectation or deception—this study proves the opposite: belief isn’t necessary for benefit.
Practical Takeaways
If your child has chronic stomach pain, ask their doctor about trying a transparent open-label placebo as a low-risk, drug-free option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
High probability
on the GRADE evidence scale
This study showed that when kids were told they were taking a sugar pill with no medicine, their tummy pain got a little better. But since they and their doctors knew they were taking the sugar pill, we can't be 100% sure it was the pill itself that helped—or if it was just because they felt cared for or expected to feel better.
Minor conflicts detected — such as academic funding or advisory roles. These are common and have a small score impact.
Strengths
- Randomized controlled trial design with crossover structure
- Intention-to-treat analysis
- Blinded outcome assessment by research assistants
Weaknesses
- No blinding of participants or clinicians (open-label design)
- Small sample size limits precision and subgroup analyses
- Potential for performance bias due to unblinded clinicians
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study did a good job by randomly assigning kids to different treatment orders and having someone else measure their pain without knowing which treatment they got. But because everyone knew what treatment they were getting, it’s like a race where some runners know the finish line—so we have to be careful trusting that the sugar pill alone made all the difference.
75 / 100
- COI disclosure+40/40
- Data availability+35/35
- Code availabilitycode not shared
60 / 100
- Randomization+20/20
- Blindingnot blinded
- Control group+15/15
- Sample size (n=30)+2.8/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 581 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design can establish causation. Although this is a randomized controlled trial, the lack of blinding introduces potential performance and detection bias, which may inflate the observed effect. However, the crossover design, intention-to-treat analysis, and blinded outcome assessment strengthen causal inference despite unblinded participants and clinicians.
Minor COI
Minor conflicts that may slightly influence the study
Several authors disclosed financial relationships with pharmaceutical companies, but these were unrelated to the study and did not involve direct funding or control over the research. The study was primarily funded by government and nonprofit sources.
Funders
Conflict Details
Innovative Health Solutions: Received personal fees outside the submitted work
Sucampo: Received personal fees outside the submitted work
Takeda: Received personal fees outside the submitted work
QOL Medical: Served as advisor outside the submitted work
Innovative Health Solutions: Served as advisor outside the submitted work
+8 more conflicts
Independent Analysis Safeguards
- Funding sources had no role in design, conduct, data analysis, interpretation, manuscript preparation, review, approval, or publication decisions
- Dr. Nurko had full access to all data and took responsibility for data integrity and accuracy
Although multiple authors have ties to pharmaceutical companies, these relationships are disclosed as external and unrelated to the study. The primary funders are government and nonprofit entities, and there is no evidence of industry influence on study design or outcomes. The study's methodology and transparency in reporting reduce bias risk.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
11 researchersIf this is your work, this is how we attribute it on Fit Body Science. Samuel Nurko is listed as the lead author.